AtheroNETH

We are happy to announce the Dutch Heart Foundation supports our collaborative AtheroNETH project that aims to personalize diagnosis and treatment by better understanding these differences.

AtheroNeth

Finding biomarkers and druggable targets for primary prevention.

Atherosclerosis is the major underlying cause of cardiovascular diseases, such as heart attacks (myocardial infarction) and (ischemic) strokes. Currently, all patients receive the same treatment, but the underlying causes of arteriosclerosis can vary significantly. We are happy to announce the Dutch Heart Foundation supports our collaborative AtheroNETH project that aims to personalize diagnosis and treatment by better understanding these differences.

Our multidisciplinary team of researchers from across our country is studying the molecular and cellular variations in arteriosclerosis and their relationship with clinical symptoms and treatment responses. We will be investigating how these variations can be detected using diagnostic methods such as biomarkers and imaging techniques.

Additionally, we will examine how different types of arteriosclerosis plaques are influenced by factors such as lipid metabolism, immune system activity, gut microbiome composition, and genetic predisposition. We aim to translate these findings into clinical practice by analyzing blood samples to predict whether specific patient groups respond differently to treatments.

The ultimate goal is to develop a personalized approach to prevention and therapy, making treatments more effective and targeted for individual patients. AtheroNETH is a remarkable collaboration of researchers from all major university medical centers in The Netherlands that bring together a variety of world-class expertise.